C
Coherus Oncology
Profile managed by Bizz IdDescription
Coherus Oncology (Coherus BioSciences) is a commercial-stage biopharmaceutical company focused on immuno-oncology. It markets the anti-PD-1 antibody Loqtorzi (toripalimab-tpzi) in the US and develops antibodies targeting the tumour microenvironment (anti-CCR8 and anti-IL-27).
Products
3 products
Casdozokitug
IL-27 antagonist monoclonal antibody. Phase 2 (1L hepatocellular carcinoma, with toripalimab + bevacizumab).
Under development
Finished product (FDF)
Verified on 2026-10-21
Tagmokitug
Anti-CCR8 monoclonal antibody. Phase 2 (4L+ colorectal cancer, with toripalimab); Phase 1 in other solid tumors.
Under development
Finished product (FDF)
Verified on 2026-10-21
Toripalimab
Brand: LOQTORZI (toripalimab-tpzi). Anti-PD-1 monoclonal antibody. Nasopharyngeal carcinoma: 1L with chemotherapy and 2L+ monotherapy. Immuno-oncology.
Aprobado FDA
Filing submitted
Finished product (FDF)
Verified on 2026-10-21